Reata Pharmaceuticals, Inc. (RETA)
RETAPrice: $172.36
Fair Value: 🔒
🔒score
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the t... more
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and c... more
Description
Shares
| Market Cap | $6.57B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | J. Warren Huff |
| IPO Date | 2016-05-26 | CAGR | -0.29% |
| Employees | 321 | Website | www.reatapharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.34% | Total Yield | -0.34% |
RETA chart loading...
Fundamentals
Technicals
| Enterprise Value | $4.35B | P/E Ratio | -66.29 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 2963.2 | P/B Ratio | -95.29 |
| P/CF Ratio | -30.65 | P/FCF Ratio | -31.64 |
| EPS | $-2.6 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 143.93% | Gross Margin | 1% |
| Operating Margin | -121.91% | Profit Margin | -140.75% |
| ROE | 0.47% | ROA | -0.61% |
| ROCE | -0.59% | Current Ratio | 6.75 |
| Quick Ratio | 6.75 | Cash Ratio | 0.72 |
| Debt/Equity | -1.82 | Interest Coverage | -6.47 |
| Altman Z Score | 5.36 | Piotroski Score | 2 |